Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.3c01250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Dinghu Weng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Zhongnan Hospital of Wuhan University, No. 169, Donghu Road, Wuchang District, Wuhan 430071, Hubei, China. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Contrast Media, Serine Endopeptidases, Gelatinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Zhongnan Hospital of Wuhan University.
Abstract (Originalsprache)
The aim of this study was to synthesize a quinoline-based MRI contrast agent, Gd-DOTA-FAPI04, and assess its capacity for targeting fibroblast activation protein (FAP)-positive tumors in vivo. Gd-DOTA-FAPI04 was synthesized by attaching a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) complex of gadolinium(III) to FAP inhibitor FAPI04. The longitudinal relaxation time (T1) of the contrast agent was measured using a Siemens Prisma 3.0T MR system, and the CCK-8 assay was performed to evaluate its potential cytotoxicity. Male nude mice bearing tumors grown from FAP-expressing fibrosarcoma cells were divided into experimental (n = 4) and control (n = 4) groups, and T1-weighted image enhancement was measured at different times (0, 10, 30, 60, 90, and 120 min) postinjection of Gd-DOTA-FAPI04. The control group received an additional preinjection of excess FAPI04. FAP expression in tumor tissue was investigated by using immunohistochemistry with an anti-FAP antibody. The longitudinal relaxivities of gadodiamide and Gd-DOTA-FAPI04 were measured to be 3.734 mM-1 s-1 and 5.323 mM-1 s-1, respectively. The CCK-8 assay demonstrated that Gd-DOTA-FAPI04 has minimal toxicity to cultured human fibrosarcoma cells. In vivo MRI showed that peak accumulation of Gd-DOTA-FAPI04 in FAP-expressing tumors occurred 1 h postinjection and could be blocked by preinjection of excess FAPI04. Immunohistochemical analysis of harvested tumor tissue supported the above findings. Gd-DOTA-FAPI04 is a promising contrast agent for in vivo imaging of FAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, Zhongnan Hospital of Wuhan University, No. 169, Donghu Road, Wuchang District, Wuhan 430071, Hubei, China.
- Hubei Provincial Engineering Research Center of Multimodal Medical Imaging Technology and Clinical Application, Wuhan 430071, Hubei, China.
- Wuhan Clinical Research and Development Center of Brain Resuscitation and Functional Imaging, Wuhan 430071, Hubei, China.
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430000, Hubei, China.
- Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, No. 169, Donghu Road, Wuchang District, Wuhan 430071, Hubei, China.
ORCID-Profile: Dinghu Weng, Liying Xu, Guobin Xu
Förderung
- Fundamental Research Funds for the Central Universities
- Zhongnan Hospital of Wuhan University
Zitieren
APA
Weng, D., Guo, R., Dong, C., Luo, Y., Qiu, D., Xu, L., & Xu, G. (2025). Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01250
Vancouver
Weng D, Guo R, Dong C, Luo Y, Qiu D, Xu L, et al. Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.3c01250
BibTeX
@article{Weng2025,
author = {Weng, Dinghu and Guo, Rong and Dong, Changling and Luo, Yuan and Qiu, Dasheng and Xu, Liying and Xu, Guobin},
title = {Magnetic Resonance Imaging of Fibroblast Activation Protein Using a Targeted Gadolinium-Based Contrast Agent},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.3c01250}
}
EUVIMED